Charles Schwab Investment Management Inc. Has $2.96 Million Stake in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Charles Schwab Investment Management Inc. lowered its holdings in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 2.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 925,660 shares of the company’s stock after selling 22,791 shares during the period. Charles Schwab Investment Management Inc. owned about 0.74% of Organogenesis worth $2,962,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bank of New York Mellon Corp increased its stake in Organogenesis by 35.5% in the fourth quarter. Bank of New York Mellon Corp now owns 418,820 shares of the company’s stock valued at $1,340,000 after acquiring an additional 109,762 shares during the period. Palumbo Wealth Management LLC acquired a new stake in Organogenesis during the fourth quarter valued at approximately $65,000. Rhumbline Advisers grew its stake in shares of Organogenesis by 7.1% in the 4th quarter. Rhumbline Advisers now owns 115,266 shares of the company’s stock valued at $369,000 after purchasing an additional 7,621 shares during the period. SG Americas Securities LLC raised its holdings in shares of Organogenesis by 66.4% in the 4th quarter. SG Americas Securities LLC now owns 41,746 shares of the company’s stock worth $134,000 after buying an additional 16,660 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in shares of Organogenesis by 54.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company’s stock worth $9,443,000 after buying an additional 1,035,120 shares during the period. Institutional investors own 49.57% of the company’s stock.

Insiders Place Their Bets

In other Organogenesis news, Director Michael Joseph Driscoll sold 25,000 shares of the business’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total value of $127,500.00. Following the completion of the transaction, the director now directly owns 166,879 shares of the company’s stock, valued at approximately $851,082.90. The trade was a 13.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 36.90% of the company’s stock.

Organogenesis Stock Down 0.6 %

Shares of NASDAQ ORGO opened at $4.67 on Friday. Organogenesis Holdings Inc. has a 1 year low of $2.17 and a 1 year high of $6.71. The firm’s 50-day moving average is $4.19 and its 200-day moving average is $3.56. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $592.29 million, a PE ratio of -77.83 and a beta of 1.66.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley lifted their target price on shares of Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.